Results 41 to 50 of about 1,844 (180)

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment

Frontiers in Bioengineering and Biotechnology, 2023
Introduction: The development of patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) offers an opportunity to study genotype-phenotype correlation of hypertrophic cardiomyopathy (HCM), one of the most common inherited cardiac
Kai Wang, Brian J. Schriver, Roozbeh Aschar-Sobbi, Alex Y. Yi, Nicole T. Feric, Michael P. Graziano   +5 more
doaj   +1 more source

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes

Clinical and Translational Science
Obstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus.
Xiaojie Wu, Nanye Chen, Peiwen Hsu, Jing Sun, Wenting Li, Qi Wang, Merali Samira, Qiong Wei, Jicheng Yu, Guoying Cao, Haijing Yang, Lili Wang, Jingjing Wang, Yi Jin, Wei Liu, Jufang Wu, Jinjie He, Cheng Lyu, Jing Zhang   +18 more
doaj   +1 more source

Prospects for remodeling the hypertrophic heart with myosin modulators

Frontiers in Cardiovascular Medicine, 2022
Hypertrophic cardiomyopathy (HCM) is a complex but relatively common genetic disease that usually arises from pathogenic variants that disrupt sarcomere function and lead to variable structural, hypertrophic, and fibrotic remodeling of the heart which ...
Lorenzo R. Sewanan, Yuichi J. Shimada
doaj   +1 more source

Metabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics

The Journal of Physiology, EarlyView.
Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran   +4 more
wiley   +1 more source

A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy

Reviews in Cardiovascular Medicine
Background: Hypertrophic cardiomyopathy (HCM) is a common hereditary cardiomyopathy. Mavacamten, a first-in-class cardiac myosin inhibitor, is considered to be a specific drug for the treatment of HCM.
Li Zheng, Xiaotong Gu, Yumiao Chen, Deping Liu   +3 more
doaj   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies.
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study

Cardiology and Therapy
Introduction Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic ...
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Ping Yang, Wei Ma, Fang Wang, Wei Jin, Xiang Cheng, Yu-Mao Chen, Yue Zhong, Yu Chen Barrett, Jing Zheng, Shuyang Zhang   +16 more
doaj   +1 more source

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Diego Ramonfaur, Alessio Gasperetti, Victoria E. Blake, Bryana Rivers, Ali A. Kassamali, Edward K. Kasper, Lili A. Barouch, Katherine C. Wu, Jose A. Madrazo, Richard T. Carrick   +9 more
doaj   +1 more source

MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA

RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 2023
Introdução: A cardiomiopatia hipertrófica (CMH) é uma das doenças cardíacas genéticas mais comuns, afetando entre 0,16% e 0,29% da população adulta geral. É uma doença genética do miocárdio e caracteriza-se por acentuada hipertrofia miocárdica que não pode ser explicada pela carga pressórica ou pela presença de desarranjo miocitário.
Caique Pereira de Paiva, Ana Clara Godinho de Freitas, Carla Lana Germinari Souza, Felipe Tochihide Iamaguti, Genon Henrique Costa Pinto, Júlia Peruzzi Iamaguti, Marina Romaquela Rodrigues, Tagstan Ribeiro Moioli, Taís Barbosa Honorato, Carollayne Mendonça Rocha   +9 more
openaire   +1 more source

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Journal of Clinical Medicine, 2023
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades
Scholtz, Smita (PD Dr. med.), Rudolph, Volker (PD Dr. med.), Reil, Jan-Christian (Dr. med.)   +2 more
openaire   +3 more sources